AXQ Capital Expands Stakes Across Five Companies
AXQ Capital Expands Stakes Across Five Companies
Anonymous
Key Points
1
Abbott Laboratories is 75.18% owned by hedge funds and other institutional investors. Recent additions included Freemont Management’s 197.2% increase, Aureus Asset Management’s 25.0% increase and Thompson Investment Management’s 786.0% increase.
2
Arch Capital Group CFO Francois Morin sold 11,010 shares at an average price of $99.32, for total proceeds of $1.09 million; the sale reduced his position by 5.62%.
3
Clover Health’s largest institutional holders include Vanguard Group, with 23.49 million shares, Geode Capital Management, with 9.79 million shares, and State Street, with 9.32 million shares; institutional investors collectively own 19.77% of the company.
4
DHT Holdings has a “Moderate Buy” consensus rating, with three analysts rating the stock Buy and two rating it Hold; the consensus price target is $19.33. Weiss Ratings recently lowered its rating from “buy (b+)” to “buy (b).”
5
Phreesia received mixed analyst coverage: Canaccord Genuity Group reaffirmed a Buy rating with a $16 price target, while Citigroup maintained a Market Perform rating and Wall Street Zen downgraded the shares from Buy to Hold.
AXQ Capital LP aggressively expanded its portfolio in the second quarter, making dramatic increases to existing stakes and establishing fresh positions across five companies. The firm boosted its Abbott Laboratories holding by 905.1% to 40,657 shares valued at $3.69 million, according to Defense World. It also acquired new stakes in Arch Capital Group ($809,000) and DHT Holdings ($641,000) while significantly growing positions in Clover Health and Phreesia.
Abbott Holdings Surge Amid Broad Institutional Support
AXQ Capital's 905.1% increase in Abbott Laboratories shares reflects a wider institutional appetite for the healthcare giant. Hedge funds and other institutional investors own 75.18% of Abbott, according to Defense World. Other major players added significant stakes: Freemont Management increased its position by 197.2%, while Thompson Investment Management jumped 786.0% in recent quarters.
Clover Health and Phreesia Face Mixed Analyst Sentiment
AXQ Capital expanded its Clover Health stake by 602.6% to 146,569 shares worth $768,000, tapping into a company where Vanguard Group holds 23.49 million shares and institutional investors control 19.77%, per Defense World. The position comes as analyst coverage remains fragmented. For Phreesia, AXQ Capital grew holdings by 214.3% to 67,000 shares ($689,000), even as Canaccord Genuity reaffirmed a Buy rating while Citigroup kept a Market Perform stance.
New Positions in Arch Capital and DHT Holdings
AXQ Capital established a $809,000 position in Arch Capital Group by purchasing 8,338 shares. The timing comes as CFO Francois Morin sold 11,010 shares at $99.32 each, netting $1.09 million and trimming his stake by 5.62%, according to Defense World. For DHT Holdings, AXQ Capital bought 38,768 shares valued at $641,000, aligning with a "Moderate Buy" consensus and a $19.33 price target from three Buy-rated analysts.
DHT Holdings Maintains Analyst Confidence Despite Rating Shifts
DHT Holdings carries a consensus "Moderate Buy" rating supported by three Buy recommendations and two Hold ratings across Wall Street, per Defense World. The consensus price target sits at $19.33. Weiss Ratings recently downgraded its stance from "buy (b+)" to "buy (b)," signaling a slight pullback in enthusiasm while maintaining overall conviction in the shipping company's prospects.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
27
Articles
6
Reach
33
Topics
A
AnonymousAuthor
